HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yongxian Hu Selected Research

bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amine

1/2022Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
1/2022BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement.
12/2021Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
1/2021Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
1/2021CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial.
1/2021Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission.
6/2020Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yongxian Hu Research Topics

Disease

22Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2022 - 01/2017
19Neoplasms (Cancer)
10/2022 - 07/2008
13Leukemia
04/2022 - 01/2015
10Multiple Myeloma
12/2022 - 06/2020
10Cytokine Release Syndrome
04/2022 - 01/2016
9Hematologic Neoplasms (Hematological Malignancy)
10/2022 - 03/2013
7Graft vs Host Disease (Graft-Versus-Host Disease)
01/2020 - 11/2012
6Lymphoma (Lymphomas)
04/2022 - 07/2008
4Infections
01/2022 - 11/2014
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
08/2021 - 01/2019
3Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2021 - 01/2018
3B-Cell Lymphoma (Lymphoma, B Cell)
10/2020 - 10/2018
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021 - 01/2020
2COVID-19
01/2021 - 01/2020
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2020 - 12/2018
2Residual Neoplasm
01/2020 - 01/2015
2Hypoxia (Hypoxemia)
01/2018 - 11/2011
2Bronchiolitis Obliterans Syndrome
03/2017 - 06/2015
1Bone Marrow Failure Disorders
10/2022
1Neoplasm Metastasis (Metastasis)
05/2022
1Capillary Leak Syndrome
01/2022
1Cytomegalovirus Retinitis
01/2022
1Retinal Detachment (Retinal Detachments)
01/2022
1Retinitis
01/2022
1Central Nervous System Diseases (CNS Diseases)
01/2022
1Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
10/2021
1Cytopenia
01/2021
1Cauda Equina Syndrome
01/2021
1Bacterial Infections (Bacterial Infection)
01/2021
1Inflammation (Inflammations)
01/2021
1Plasma Cell Leukemia
01/2021
1Neutropenia
01/2021
1Pancytopenia
01/2021
1Virus Diseases (Viral Diseases)
01/2021
1Macrophage Activation Syndrome
01/2021
1Blast Crisis (Blast Phase)
06/2020
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
06/2020
1Fever (Fevers)
01/2020
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
01/2020
1Dyspnea (Shortness of Breath)
01/2019
1Diarrhea
09/2018
1Exanthema (Rash)
09/2018
1Lymphopenia (Lymphocytopenia)
09/2018
1Hydrothorax
02/2018

Drug/Important Bio-Agent (IBA)

45Chimeric Antigen ReceptorsIBA
04/2022 - 01/2016
7bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
01/2022 - 06/2020
7CytokinesIBA
12/2021 - 03/2017
6B-Cell Maturation AntigenIBA
01/2022 - 06/2020
3Biomarkers (Surrogate Marker)IBA
05/2022 - 01/2021
3Interleukin-6 (Interleukin 6)IBA
01/2021 - 02/2018
3Adrenal Cortex Hormones (Corticosteroids)IBA
01/2021 - 01/2020
3AntigensIBA
12/2020 - 11/2014
2Lenalidomide (CC 5013)FDA Link
01/2022 - 01/2021
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
10/2021 - 01/2021
2Dasatinib (BMS 354825)FDA Link
01/2021 - 06/2020
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2020 - 11/2012
2DecitabineFDA Link
03/2019 - 01/2019
2InterferonsIBA
12/2018 - 03/2017
2SteroidsIBA
09/2018 - 01/2017
2BasiliximabFDA Link
09/2018 - 01/2017
2Etanercept (Enbrel)FDA Link
09/2018 - 01/2017
2Interleukin-2 (IL2)IBA
03/2017 - 07/2008
2CateninsIBA
01/2017 - 01/2015
1pomalidomideIBA
12/2022
1Biological ProductsIBA
10/2022
1Circular RNAIBA
05/2022
1CholesterolIBA
04/2022
1AlbuminsIBA
04/2022
1ponatinibIBA
01/2022
1CalcineurinIBA
01/2022
1venetoclaxIBA
01/2022
1Thomsen-Friedenreich antibodiesIBA
01/2021
1Circulating Tumor DNAIBA
01/2021
1Sorafenib (BAY 43-9006)FDA Link
01/2021
1GlobulinsIBA
01/2021
1NF-kappa B (NF-kB)IBA
01/2021
1Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2021
1Interleukin-10 (Interleukin 10)IBA
01/2021
1Interleukin-18 (Interleukin 18)IBA
01/2021
1fms-Like Tyrosine Kinase 3IBA
01/2021
1Monoclonal AntibodiesIBA
12/2020
1fludarabineIBA
10/2020
1Inosine Triphosphate (ITP)IBA
06/2020
1tocilizumab (atlizumab)FDA Link
01/2020
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
12/2019
1ruxolitinibIBA
12/2019
1Imatinib Mesylate (Gleevec)FDA Link
12/2018
1DNA (Deoxyribonucleic Acid)IBA
02/2018
1cobaltous chloride (cobalt(II)chloride)IBA
01/2018
1plerixaforFDA Link
01/2018

Therapy/Procedure

39Therapeutics
12/2022 - 01/2015
15Hematopoietic Stem Cell Transplantation
01/2022 - 11/2012
8Drug Therapy (Chemotherapy)
08/2021 - 05/2018
7Transplantation
01/2020 - 01/2016
5Immunotherapy
01/2022 - 07/2008
4Stem Cell Transplantation
12/2020 - 12/2017
2Haploidentical Transplantation
03/2019 - 01/2019
1Platelet Transfusion (Blood Platelet Transfusions)
01/2021
1Cell- and Tissue-Based Therapy (Cell Therapy)
01/2020
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/2020